Last reviewed · How we verify
NCT07530016
Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma
NA trial testing Ligustrazine - tranexamic acid - aloe polysaccharide composite gel in Melasma in 10 participants. Not yet recruiting.
25 December 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xinxiang Medical College |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 12 August 2026 |
| Primary completion | 25 December 2027 |
| Estimated completion | 16 November 2028 |
Drugs / interventions tested
- Ligustrazine - tranexamic acid - aloe polysaccharide composite gel
Conditions studied
- Melasma — all drugs for Melasma →
- Treatment of Stable Melasma — all drugs for Treatment of Stable Melasma →
- Tranexamic Acid — all drugs for Tranexamic Acid →
- Laurocapram — all drugs for Laurocapram →
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Who can join
Adults 18 to 50, female only, with Melasma or Treatment of Stable Melasma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Melasma is a common pigmentation disorder among young and middle-aged women, characterized by symmetrical brown-black patches on the face. It is related to genetics, ultraviolet radiation, endocrine factors and inflammation, and can lead to psychological problems and affect quality of life. Current treatments such as hydroquinone stimulation, laser therapy, and oral tranexamic acid have a high recurrence rate and poor compliance. The new gel formulation, which combines tranexamic acid (to inhibit tyrosinase), aloe polysaccharides (anti-inflammatory and repair), and lauric azon (promotes penetration), is expected to enhance efficacy and reduce side effects. This study aims to explore its clinical efficacy and synergistic mechanism, providing new strategies for the treatment of Melasma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07530016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melasma
Currently open trials in the same condition.
- NCT06845540 — Oral Metformin for Treating Melasma in Latin American Women · Phase 1, PHASE2 · recruiting
- NCT06644157 — Treatment and Prevention of Melasma Relapses by Using 1064nm 650 Microsecond Laser · NA · active not recruiting
- NCT07034560 — Effectiveness of Oral Melatonin vs Oral Tranexamic Acid in the Treatment and Recurrence of Melasma · Phase 4 · active not recruiting
- NCT06516419 — Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
Other The First Affiliated Hospital of Xinxiang Medical College trials
Trials by the same sponsor.
- NCT07530003 — HUMSCs Combined With Col I to Third-Degree Burn Wound · Phase 1, PHASE2 · recruiting
- NCT07476534 — Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression · not yet recruiting
- NCT07347496 — A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined · Phase 4 · not yet recruiting
- NCT07376577 — Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP · NA · not yet recruiting
- NCT07325123 — Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07530016 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xinxiang Medical College
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07530016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing